GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GC Biopharma 006280.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

136,700

-2.43%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About GC Biopharma

Its shares trade on KRX under the ticker 006280.KS. It has been listed since 1 August 1989. In the fiscal year to 31 December 2025, it reported revenue of ₩1.99trn and a net loss of ₩4.67bn. At that date it held total assets of ₩2.97trn and shareholders' equity of ₩1.22trn.

Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Yongin, Gyeonggi-Do. The firm mainly manufactures pharmaceutical products including blood products, general products, vaccines, over the counter (OTC) drugs, diagnostic reagents, placental injections, cell therapies, vaccine fertilized eggs and blood diagnostic products, among others. The firm also provides genome analysis services.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
1 Aug 1989

Leadership

Pay as last reported

  • Mr. Yil Seop HuhChairman, since 2004₩950.0m
  • Mr. Eun Cheol HuhPresident, Chief Executive Officer, Director, since 2010₩899.0m
  • Mr. Yeong Tae LeeInternal Auditor
  • Mr. Yin Gyu LeeHead of Factory of Hwasun Factory
  • Mr. Hyeong Jun ParkHead of Factory of Ochang Factory
  • Mr. Jae Wuk JungDirector
  • Mr. Wung ShinDirector
  • Mr. Seung Ho YimDirector, since 2020
  • Mr. Chun Wu LeeNon-Executive Independent Director
  • Ms. Jin Hui LeeNon-Executive Independent Director
  • Mr. Gi Jun ParkNon-Executive Independent Director
  • Mr. Seong Hun ShimNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
84
Environment
99
Social
99
Governance
54
Direct emissions (scope 1)
10,804 t
Energy emissions (scope 2)
54,001 t
Women in the workforce
26.01232%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Green Cross Corp manufactures blood products and vaccines in Yongin.
  • The firm provides genome analysis services to diverse clients.
  • Placental injections and cell therapies are key product segments.

Weaknesses

  • Over the counter drugs represent a significant portion of sales.
  • Diagnostic reagents require continuous technological updates and investment.
  • Vaccine fertilized eggs involve complex regulatory compliance processes.

Opportunities

  • Expanding genome analysis services could increase revenue streams.
  • Growing demand for cell therapies offers new market potential.
  • Increasing need for diagnostic reagents supports business growth.

Threats

  • Competitors in the biotechnology sector may launch similar products.
  • Regulatory changes could impact the sale of blood products.
  • Fluctuating costs of raw materials affect manufacturing margins.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.